Table 6. Analysis of factors influencing... | American Society of Hematology

Table 6.

Analysis of factors influencing survival

	N	Median survival, mo	4-year survival, %	P
Without quinine	212	22	39.3 ± 3.4	.3
With quinine	213	30	43.7 ± 3.6	.3
BMT, intent to treat	82	NR	63.0 ± 5.4	.07
ICC, intent to treat	262	33	46.1 ± 3.2	.07
Age younger than 46 y	247	31	46.7 ± 3.3	.006
Age older than 45 y	178	18	34.5 ± 3.7	.006
FAB 2 and 4	225	36	47.4 ± 3.4	.003
FAB other	200	20	34.8 ± 3.5	.003
Performance status less than 3	327	30	45.4 ± 2.8	.001
Performance status higher than 2	97	15	29.4 ± 4.8	.001
WBC count lower than 30 G/L	281	36	46.9 ± 3.0	< .0001
WBC count higher than 30 G/L	144	15	31.3 ± 4.0	< .0001
Karyotype				.003
Normal	180	27	40.8 ± 3.8
Good	64	NR	58.7 ± 6.5
Intermediate	61	22	39.5 ± 6.4
Poor	59	12	26.8 ± 5.8
Rh123 efflux positive	54	18	39.1 ± 6.6	.33
Rh123 efflux negative	106	34	46.2 ± 5.0	.33

	N	Median survival, mo	4-year survival, %	P
Without quinine	212	22	39.3 ± 3.4	.3
With quinine	213	30	43.7 ± 3.6	.3
BMT, intent to treat	82	NR	63.0 ± 5.4	.07
ICC, intent to treat	262	33	46.1 ± 3.2	.07
Age younger than 46 y	247	31	46.7 ± 3.3	.006
Age older than 45 y	178	18	34.5 ± 3.7	.006
FAB 2 and 4	225	36	47.4 ± 3.4	.003
FAB other	200	20	34.8 ± 3.5	.003
Performance status less than 3	327	30	45.4 ± 2.8	.001
Performance status higher than 2	97	15	29.4 ± 4.8	.001
WBC count lower than 30 G/L	281	36	46.9 ± 3.0	< .0001
WBC count higher than 30 G/L	144	15	31.3 ± 4.0	< .0001
Karyotype				.003
Normal	180	27	40.8 ± 3.8
Good	64	NR	58.7 ± 6.5
Intermediate	61	22	39.5 ± 6.4
Poor	59	12	26.8 ± 5.8
Rh123 efflux positive	54	18	39.1 ± 6.6	.33
Rh123 efflux negative	106	34	46.2 ± 5.0	.33

NR indicates not reached.